Stephen K. Carter, M.D. Joins NaPro Board of Directors
10 Março 2004 - 11:35AM
PR Newswire (US)
Stephen K. Carter, M.D. Joins NaPro Board of Directors BOULDER,
Colo., March 10 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics,
Inc. announced today the appointment of Stephen K. Carter, M.D. to
its Board of Directors effective March 9, 2004. Dr.Carter has over
forty years of experience in oncology and pharmaceutical drug
development as a practicing clinician, medical researcher, Clinical
Professor of Medicine (University of California, San Francisco) and
a senior member of the National CancerInstitute (NCI). In addition,
Dr. Carter served as a pharmaceutical executive for thirteen years
at Bristol-Myers Squibb where he held the position of Senior Vice
President, Worldwide Clinical Research and Development. At the
National Cancer Institute Dr. Carter held the position of Deputy
Director, Division of Cancer Treatment, where, for over a decade,
he helped shape the cancer therapy evaluation branch of the NCI.
Later, at Bristol- Myers Squibb, Dr. Carter was responsible for the
development of a number of cancer chemotherapeutics including both
Carboplatin and Taxol. "All of us at NaPro welcome the integrity,
broad experience, and judgment that Dr. Carter brings to both our
commercial and medical deliberations as we advance our preclinical
portfolio of anticancer agents into human clinical trials over the
next year," commented Leonard Shaykin, Chairman and Chief Executive
Officer of NaPro. "We are honored by Dr. Carter's participation in
the Company and look forward to his contributionon the Board." In a
related matter, Marc J. Ostro, Ph.D., a Managing Director of T.L.
Ventures, has decided to resign from the Board of NaPro
BioTherapeutics effective March 11, 2004. About NaPro
BioTherapeutics NaPro BioTherapeutics, Inc., is a life science
company focused on the development of therapies for the treatment
of cancer and hereditary disease. Forward Looking Statements The
statements in this news release that are not historical facts are
forward-looking statements that represent management's beliefs and
assumptions as of the date of this news release, based on currently
available information. Although the Company believes that the
expectations reflected in such forward- looking statements are
reasonable, it cannot assure that these expectations will prove to
be correct. Such statements involve risks and uncertainties
including: risks associated with development of anti-cancer agents,
including competition from companies in similar businesses,
limitations on the ability to market products because of the
intellectual property rights of third parties, the ability to
obtain, maintain and enforce patents; the costs of continuing
development of any or all of the Company's development programs;
the timing of when those programs will enter the clinic; the
successful commercialization of the Company's platform
technologies; the fact that the Company's business will require
substantial additional investment that the Company has not secured;
and the risk that the Company's cash not be sufficient to fund the
Company's strategic plans for the initial development new
proprietary therapeutic candidates; and all of those factors
identified under the captions "Risk Factors," "Special Note
Regarding Forward Looking Statements" or "Cautionary Note Regarding
Forward Looking Statements" in the Company's documents filed from
time to time with the SEC, including the Company's registration
statement on Form S-3, as amended, dated August 8, 2003, its Annual
Report on Forms 10-K and 10-K/A for the year ending December 31,
2002 filed with the SEC on March 27, April 30, August 8 and October
24, 2003, and its Quarterly Report on Form 10-Q for the quarter
ended October 1, 2003 filed with the Securities and Exchange
Commission on November 14, 2003. Should one or more of these risks
materialize (or the consequences of such a development worsen), or
should the underlying assumptions prove incorrect, actual results
could differ materially from those forecasted or expected. The
Company disclaims any intention or obligation to update publicly or
revise such statements whether as a result of new information,
future events or otherwise. DATASOURCE: NaPro BioTherapeutics, Inc.
CONTACT: L. Robert Cohen, Vice President, Investor Relations of
NaPro BioTherapeutics, Inc., +1-212-218-8715; or Investors, Lilian
Stern of Stern Investor Relations, +1-212-362-1200; or Media, Peter
Steinerman, +1-516-374-3031, both for NaPro BioTherapeutics, Inc.
Web site: http://www.naprobio.com/
Copyright
Napro Biotherapeutics (NASDAQ:NPRO)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Napro Biotherapeutics (NASDAQ:NPRO)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024